← All stories
Health, Longevity & Biohacking

Brain Contains 20 Times More Cholesterol Than Liver Despite Low Blood Levels

Peter Attia Drive · #395 - Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer's disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D. · June 8, 2026
Brain Contains 20 Times More Cholesterol Than Liver Despite Low Blood Levels
Peter Attia Drive
Peter Attia Drive
#395 - Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer's disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D.
"The brain, of all the organs in the body, has 20 times more cholesterol than does the liver. The brain has like 20 to 25 grams. There's like 140 grams total in the body of cholesterol, where the liver would have 3 to 5 grams."
Dayspring revealed the brain stores vastly more cholesterol than any other organ, containing 20-25 grams compared to the liver's 3-5 grams. This storage occurs even in children with LDL cholesterol as low as 30 mg/dL during peak brain growth, definitively proving brain development doesn't depend on circulating cholesterol levels.

About this episode

On this episode of The Drive Podcast, host Dr. Peter Attia conducts an in-depth technical discussion with lipidologist Dr. Tom Dayspring on cholesterol metabolism in the brain and its relationship to Alzheimer's disease. The conversation challenges fundamental misconceptions about brain cholesterol by establishing that the brain's cholesterol system operates completely independently from peripheral blood cholesterol levels. Dayspring explains that ApoB particles carrying most circulating cholesterol cannot cross the blood-brain barrier, and that the brain contains 20 times more cholesterol than the liver despite children having LDL levels as low as 30 mg/dL during peak brain growth. The discussion centers on how the brain uses ApoE-containing lipoproteins rather than ApoB particles for cholesterol transport, and why the ApoE4 genotype creates dysfunctional lipoproteins that cannot properly deliver cholesterol to neurons, triggering beta amyloid and tau production. Dayspring presents evidence from statin meta-analyses showing these drugs cause no brain harm and may reduce Alzheimer's incidence, contradicting widespread fears about cognitive impairment from cholesterol-lowering therapy. The physicians discuss biomarkers like desmosterol and 24S-hydroxycholesterol that can track brain cholesterol synthesis and health through blood tests. They also explore the role of omega-3 fatty acids, ezetimibe's surprising potential brain benefits despite working in the gut, and new evidence that the CTEP inhibitor obesetrapib improves Alzheimer's biomarkers. The episode provides a molecular-level understanding of how cholesterol dysregulation drives neurodegeneration and why aggressive lipid lowering may protect rather than harm the brain.

Key takeaways

More stories More from Peter Attia Drive